ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1052

Time Trends in Comorbidities Among Patients with Rheumatoid Arthritis Compared to the General Population

Cynthia S. Crowson1, John M. Davis III2, Brittny T. Major1, Eric L. Matteson2, Terry M. Therneau3 and Sherine E. Gabriel4, 1Health Sciences Research, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Comorbidity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) related comorbidities are major determinants of morbidity and mortality. Little is known regarding the trends in these conditions. The purpose of our study was to examine whether the risk of comorbidities in RA patients has changed in recent years.

Methods: A population-based inception cohort of RA subjects who fulfilled 1987 ACR criteria for RA in 1980-2007 and a comparison cohort of subjects without RA of similar age and sex were assembled and followed until death, migration, or 7-1-2012. The presence of Charlson comorbidities (i.e., myocardial infarction, heart failure [HF], peripheral vascular disease [PVD], cerebrovascular disease, dementia, chronic obstructive pulmonary disease [COPD], ulcer, liver disease, diabetes mellitus, chronic kidney disease [CKD], and cancer) was ascertained by medical record review. Chi-square tests were used to assess trends in comorbidities present at baseline (i.e., RA incidence/index date) according to time period (1980-84 vs. 1995-2007) in each cohort. Cumulative incidence adjusted for competing risk of death was used to assess the risk of developing comorbidities during follow-up.

Results: The study included 813 RA patients and 813 non-RA subjects. Age and sex were similar in both cohorts and both time periods (mean age 56 [SD 16] years, 69% women). More patients with incident RA in the 1995-2007 time period had ≥1 Charlson comorbidity at baseline than those in the 1980-1994 time period (56% vs 44%; p<0.001). However, this trend was similar in the non-RA cohort (50% vs. 38%; p<0.001). Comorbidities that increased over time included cancer, CKD, COPD and liver disease in both cohorts, PVD and cerebrovascular disease in RA and HF in non-RA. However, among those with no comorbidities at baseline, the cumulative incidence of ≥1 Charlson comorbidity by 10 years later was lower among those with incident RA in the 1995-2007 time period than the 1980-1994 time period (22% vs. 27%; p=0.008), with similar findings for non-RA (17% vs. 25%; p=0.03). Considering both prevalent and incident comorbidities, there was no significant change over time in the cumulative incidence of ≥1 comorbidity at 10 years in the RA (76% in 1995-2007 vs. 71% in 1980-1994; p=0.11) or non-RA cohorts (67% in 1995-2007 vs. 64% in 1980-1994; p=0.07).

Conclusion: Although the prevalence of comorbidities at baseline was higher in more recent years in both the RA and non-RA cohorts, the rate of occurrence of new comorbidities has declined over time.  This may indicate earlier recognition and improved management of comorbidities both in the RA and in the general population.


Disclosure:

C. S. Crowson,
None;

J. M. Davis III,
None;

B. T. Major,
None;

E. L. Matteson,
None;

T. M. Therneau,
None;

S. E. Gabriel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-trends-in-comorbidities-among-patients-with-rheumatoid-arthritis-compared-to-the-general-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology